TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00783601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: placebo + montelukast
Description: Two placebo tablets in the matching image of MK0524 150 mg and one 10 mg tablet montelukast once daily for 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo
Description: During the double-blind treatment periods, patients receive either two placebo tablets in the matching image of MK0524 150 mg or one placebo tablet in the matching image of montelukast 10 mg in a crossover manner. During the washout period before the crossover to the opposite treatment sequence, patients receive two placebo tablets in the matching image of MK0524 150 mg and one placebo tablet in the matching image of montelukast 10 mg once daily for two weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo
Description: During the double-blind treatment periods, patients receive either two placebo tablets in the matching image of MK0524 150 mg or one placebo tablet in the matching image of montelukast 10 mg in a crossover manner. During the washout period before the crossover to the opposite treatment sequence, patients receive two placebo tablets in the matching image of MK0524 150 mg and one placebo tablet in the matching image of montelukast 10 mg once daily for two weeks.
Study: NCT03323346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disulfiram
Description: Patients will take one pill of disulfiram (Antabus) daily at a dose of 400 mg continually during the treatment phase (from day 0 till End of treatment Visit). In case of intolerance, lower dose up to 200 mg per day is allowed.~Copper supplementation will be given separately from disulfiram; in the morning with patients´breakfast. Patients will take one pill of copper dietary supplement (for instance Copper Star, STARLIFE) corresponding to 2 mg of elementary copper.
Study: NCT01669447

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ranibizumab
Description: Interventional study, prospective will be conducted in a single eye of twenty consecutive patients who will receive intravitreal ranibizumab for neovascular membrane active subfoveal choroidal active due to AMD and visual acuity of 20/40 and 20/320.~To establish the presence of active neovascularization evaluated the presence of leakage seen on fluorescein angiography and fluid, as seen in optical coherence tomography (OCT), located both intra and subretinal, or below the retinal pigment epithelium.~Treatment with ranibizumab will be offered after extensive Discussing the pathogenesis of AMD, the treatment alternatives, as well as the possible risks of treatment with ranibizumab. Term of consent shall be obtained prior to treatment.
Study: NCT01379742

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RapidStrand seeds for use with 18g needle
Description: Rapidstrand seeds are standard size and are used with 20 g needles

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RapidStrand seeds for use with 18g needle
Description: Rapidstrand seeds are standard size and are used with 20 g needles

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ThinStrand
Description: ThinStrand seeds are smaller in diameter and used with 20g needles

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ThinStrand
Description: ThinStrand seeds are smaller in diameter and used with 20g needles
Study: NCT01356797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hypobaric levobupivacaine with fentanyl
Description: SSSA with 4 mg hypobaric levobupivacaine 0,13% with 10 mcg fentanyl

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hyperbaric bupivacaine 0,5%
Description: SUSA with 4 mg hyperbaric bupivacaine 0.5%
Study: NCT02934906

Intervention type: PROCEDURE
Intervention: Standard clinical treatment, including intravenous immunoglobulin and/or platelet transfusion
Description: Observational study.

Intervention type: PROCEDURE
Intervention: Standard clinical treatment, including intravenous immunoglobulin and/or platelet transfusion
Description: Observational study.
Study: NCT02555033

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: traditional resistance training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instability resistance training
Description: training under unstable conditions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instability resistance training
Description: training under unstable conditions
Study: NCT01317745

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Phosphate Buffered Saline (PBS) diluent
Description: Placebo/diluent provided be sanofi pasteur
Study: NCT01702168

Intervention type: OTHER
Intervention: Provider training: Cognitive Processing Therapy (CPT)
Study: NCT04334213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-501
Description: QD, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-501
Description: QD, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D745, D150
Description: QD, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D745, D150
Description: QD, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-501, D745, D150
Description: QD, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-501, D745, D150
Description: QD, PO
Study: NCT01317745

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Phosphate Buffered Saline (PBS) diluent
Description: Placebo/diluent provided be sanofi pasteur

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Phosphate Buffered Saline (PBS) diluent
Description: Placebo/diluent provided be sanofi pasteur
Study: NCT04334213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-501, D745, D150
Description: QD, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-501, D745, D150
Description: QD, PO
Study: NCT04863196

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laser therapy Treatment Group
Description: laser in gastric mucosa lesion

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Barrier Dust Treatment Group
Description: barrier powder in gastric mucosa lesion
Study: NCT03528005

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-domain intervention
Description: 60 minutes cognitive training, 45 minutes physical exercise, 15 diet nutrition and intermittent disease management consultation
Study: NCT01498016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Iv busulfan 1.6mg/kg q12h D1- D4
Study: NCT01393938

Intervention type: OTHER
Group type: OTHER
Intervention: Three-dimensional ultrasound
Description: Immediately following the standard of care 2D-US, for approximately 15 min.
Study: NCT01447303

Intervention type: OTHER
Intervention: Subject outcomes following viscosupplementation of the knee
Description: The study subject outcomes (WOMAC, VAS, SF-36, Chair rise, Stair climb, Six minute walk and Gait analysis) measured at 1, 3, 6 and 12 months following viscosupplementation of the knee
Study: NCT02833948

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Drug: Clopidogrel 75 mg OD for first 90 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: Drug: Rivaroxaban (Xarelto):~10 mg OD (once-daily)
Study: NCT03388957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: This drug will be given before the extraction procedure
Study: NCT02668029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxygen
Description: information already included in arm/group descriptions.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: medical air
Description: Placebo
Study: NCT01554514

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: rituximab intravenously 100 mg every week for four doses
Study: NCT01317745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MF59 Adjuvant
Description: Adjuvant/diluent manufactured by Novartis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MF59 Adjuvant
Description: Adjuvant/diluent manufactured by Novartis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MF59 Adjuvant
Description: Adjuvant/diluent manufactured by Novartis
Study: NCT02115360

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcitonin
Description: Under full aseptic conditions, the epidural space was identified at the L 2-3 or L 3-4 lumbar interspace using the loss-of-resistance to saline technique using 16-gauge Tuohy needle. A test-dose of 3 mL of a 2% solution of lidocaine with adrenaline (1:200,000) will be given to exclude subarachnoid or intravenous catheter placement. An injection of a2 ml hyperbaric bupivacaine will be injected into the subarachnoid space through 25 gauge spinal needle, then 15ml 0.5% bupivacaine, 100 micrograms of fentanyl and 1ml normal saline will be injected epidurally in Bupivacain- fentanyl (BF) Group, then a 16G Portex catheter was inserted for post- operative analgesia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Under full aseptic conditions, the epidural space was identified at the L 2-3 or L 3-4 lumbar interspace using the loss-of-resistance to saline technique using 16-gauge Tuohy needle. A test-dose of 3 mL of a 2% solution of lidocaine with adrenaline (1:200,000) will be given to exclude subarachnoid or intravenous catheter placement. An injection of a2 ml hyperbaric bupivacaine will be injected into the subarachnoid space through 25 gauge spinal needle, then 15ml 0.5% bupivacaine, 100 micrograms of fentanyl and 1ml normal saline will be injected epidurally in Bupivacain- fentanyl (BF) Group, then a 16G Portex catheter was inserted for post- operative analgesia.
Study: NCT00300365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Pioglitazone, initially 30 mg, then titrated to 45 mg/day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pioglitazone placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niacin ER
Description: Niacin ER 2.0 g/day
Study: NCT01317745

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H5N1 Antigen
Description: Subvirion inactivated monovalent influenza A/H5N1 (Hemagglutinin (HA) of A/Indonesia/05/2005) virus vaccine manufactured by sanofi pasteur, at 2 doses levels 21 days apart, , administered at 3.75, 7.5, or 15mcg, with either MF59 adjuvant or PBS.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H5N1 Antigen
Description: Subvirion inactivated monovalent influenza A/H5N1 (Hemagglutinin (HA) of A/Indonesia/05/2005) virus vaccine manufactured by sanofi pasteur, at 2 doses levels 21 days apart, , administered at 3.75, 7.5, or 15mcg, with either MF59 adjuvant or PBS.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H5N1 Antigen
Description: Subvirion inactivated monovalent influenza A/H5N1 (Hemagglutinin (HA) of A/Indonesia/05/2005) virus vaccine manufactured by sanofi pasteur, at 2 doses levels 21 days apart, , administered at 3.75, 7.5, or 15mcg, with either MF59 adjuvant or PBS.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: H5N1 Antigen
Description: Subvirion inactivated monovalent influenza A/H5N1 (Hemagglutinin (HA) of A/Indonesia/05/2005) virus vaccine manufactured by sanofi pasteur, at 2 doses levels 21 days apart, , administered at 3.75, 7.5, or 15mcg, with either MF59 adjuvant or PBS.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: H5N1 Antigen
Description: Subvirion inactivated monovalent influenza A/H5N1 (Hemagglutinin (HA) of A/Indonesia/05/2005) virus vaccine manufactured by sanofi pasteur, at 2 doses levels 21 days apart, , administered at 3.75, 7.5, or 15mcg, with either MF59 adjuvant or PBS.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: H5N1 Antigen
Description: Subvirion inactivated monovalent influenza A/H5N1 (Hemagglutinin (HA) of A/Indonesia/05/2005) virus vaccine manufactured by sanofi pasteur, at 2 doses levels 21 days apart, , administered at 3.75, 7.5, or 15mcg, with either MF59 adjuvant or PBS.
Study: NCT01788670

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ethanol

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ethanol

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water
Study: NCT04716387

Intervention type: OTHER
Intervention: Standard LLIN
Description: Long-lasting insecticidal net containing alphacypermethrin, a pyrethroid insecticide, and manufactured by Shobikaa Impex Private Limited.

Intervention type: OTHER
Intervention: Piperonyl butoxide ITN
Description: Insecticide treated net containing permethrin, a pyrethroid, and piperonyl butoxide, an insecticide synergist, manufactured by Sumitomo Chemical.

Intervention type: OTHER
Intervention: Pyriproxyfen ITN
Description: Insecticide treated net containing alpha-cypermethrin, a pyrethroid, and pyriproxyfen, an insect growth regulator, manufactured by Disease Control Technologies.
Study: NCT00300365

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Niacin ER
Description: Niacin ER 2.0 g/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: asprin 325 mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aspirin
Description: asprin 325 mg/day
Study: NCT00641082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clevudine
Description: 30mg for 48 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adefovir dipivoxil
Description: 10mg for 48 weeks
Study: NCT03255876

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Enriched pomegranate juice
Description: Pure pomegranate juice enriched with grape seed and apple peel extract (200 ml) to be consumed with 109 g of bread

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo beverage
Description: Beverage containing the same type and amount of carbohydrates as pomegranate juice and similar flavor (200 ml) to be consumed with 109 g of bread
Study: NCT02796885

Intervention type: OTHER
Intervention: no intervention - observational study

Intervention type: OTHER
Intervention: no intervention - observational study

Intervention type: OTHER
Intervention: no intervention - observational study
Study: NCT02299076

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral economics incentives
Description: Behavioral economics-informed incentives to promote engagement and outcomes in a smoking cessation intervention.

Intervention type: OTHER
Group type: OTHER
Intervention: Minimal incentives
Description: Minimal financial incentives to promote engagement and outcomes in a smoking cessation intervention.
Study: NCT02078648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SL-701; poly-ICLC (polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethyl cellulose)
Description: 1.0 mL injection taken from 0.7 mL of SL-701 mixed at a 1:1 (v/v) ratio with 0.7 mL of Montanide. Preferred site of SC injection is in the right or left upper arms.~Within 20 minutes following the administration of the SL-701 emulsion, poly-ICLC should be administered as an IM injection in the same extremity (within 3 cm whenever possible) as was administered the SL-701 (deltoid muscle, unless contraindicated).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Following the administration of SL-701 and poly-ICLC, bevacizumab will be administered IV at a dose of 10 mg/kg. Bevacizumab infusions may occur over 30, 60 or 90 minutes in accordance with institutional practices and guidelines.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SL-701 + GM-CSF
Description: 1.0 mL injection taken from 0.7 mL of SL-701 mixed at a 1:1 (v/v) ratio with 0.7 mL of Montanide. Preferred site of SC injection is in the right or left upper arms.~150 μg GM-CSF should be administered as a SC injection immediately after SL-701 emulsion administration and within 1 cm from the center of the SL-701 emulsion injection site.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod
Description: Within 5 minutes following the administration of the SL-701 emulsion, approximately 125 mg of imiquimod cream will be applied topically on the injection site. The imiquimod cream should be rubbed in until the cream is no longer visible.
Study: NCT03169257

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: diet plus physical activity
Description: OB subjects will undergo an isocaloric Mediterranen balanced diet plus a daily aerobic training for at least 60 minutes. All the evaluations will be performed at baseline and after 6 and 12 months of this behavioral therapy. To assess food consumption, foods will be divided according to the classic basic food groups by the Italian Institute of Research on Food and Nutrition. Food frequencies questionnaires, validated for a wide range of ages, will be also completed by parents. Physical activity will be recorded by parents daily on a specific questionnaire.
Study: NCT02270255

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Superior hypogastric nerve block
Description: 21g Chiba needle advanced into the superior hypogastric plexus via an anterior infraumbilical approach using the arterial catheter as a fluoroscopic landmark to target the vertebral body below.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.75% Ropivacaine
Description: 20 ml of 0.75% Ropivacaine
Study: NCT04716387

Intervention type: OTHER
Intervention: Chlorfenapyr ITN
Description: Insecticide-treated nets containing two active ingredients: alpha-cypermethrin, a pyrethroid insecticide, and chlorfenapyr, a pyrrole insecticide, manufactured by BASF.
Study: NCT03713203

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pagetex PDT
Description: 2 to 4 sessions of PDT treatment during 2.5 hours after application of Metvixia and incubation under occlusive coat.
Study: NCT01328821

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CTP-499
Description: 600 mg, 1200 mg, 1800 mg and 2400 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CTP-499
Description: 400 mg immediate release capsule
Study: NCT02487238

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Enema
Description: Active intervention.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline Enema
Description: Placebo comparator.
Study: NCT00454987

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Menitorix
Description: Menitorix was only administered to subjects of the group Meningitic+Hiberix group at 40 to 43 months of age.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix IPV
Description: Infanrix IPV was administered according to the manufacturer's instructions to UK subjects at 40 to 43 months of age.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix IPV
Description: Infanrix IPV was administered according to the manufacturer's instructions to UK subjects at 40 to 43 months of age.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix IPV
Description: Infanrix IPV was administered according to the manufacturer's instructions to UK subjects at 40 to 43 months of age.
Study: NCT01476696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel
Description: Administered orally
Study: NCT03038815

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VACOped
Description: restriction of ankle joint motion

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VACOped
Description: restriction of ankle joint motion

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ortho Tri
Description: restriction of ankle joint motion

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ortho Tri
Description: restriction of ankle joint motion
Study: NCT03054870

Intervention type: DRUG
Group type: OTHER
Intervention: Xe-133
Description: Xe-133 ventilation scintigraphy

Intervention type: DRUG
Group type: OTHER
Intervention: Technegas
Description: Technegas ventilation scintigraphy
Study: NCT01275274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retinoic acid
Description: Patients will be started at half the recommended dose of retinoic acid for the treatment of acute promyelocytic leukemia (APL), i.e. 22.5mg/m2/day orally in two divided doses, to minimize the risk of adverse events. If there is no decrease in PR3/MPO gene expression to a fold change of \< 2 by quantitative polymerase chain reaction(QT-PCR) technique for PR3 at the end of 4 weeks, the dose will be increased to 45 mg/m2/day in two divided doses for an additional 8 weeks. If the patient shows a decrease in PR3/MPO gene expression to \< 2 at 4 weeks, the patient will remain on the same dose for the remainder of 12 weeks. All patients will be followed for a total of 12 months for safety evaluations and to assess changes in disease activity and the incidence of disease relapse.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: maintenance therapy with azathioprine or mycophenolate mofetil with or without small dose prednisone. Dose, frequency and duration depend on disease activity (partial or complete remission).
Study: NCT02270255

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Subcutaneous injection
Description: Injection into subcutaneous tissues in periumbilical region

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: 1% Xylocaine
Description: 5ml of 1% Xylocaine
Study: NCT01185938

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: One oral single dose of rosuvastatin of 40 mg at admission and then 20 mg/day for 1 month.
Study: NCT01214018

Intervention type: OTHER
Intervention: Questionnaires and interview
Description: Questionnaires and interview

Intervention type: OTHER
Intervention: Questionnaires and interview
Description: Questionnaires and interview

Intervention type: OTHER
Intervention: Questionnaires and interview
Description: Questionnaires and interview
Study: NCT01176266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asfotase alfa
Study: NCT00149747

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Aerobic Physical Activity
Description: Moderate-Intensity Aerobic Physical Activity. 4+ days per week, 60+ minutes per day, moderate or greater intensity physical activity

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Health Education Class
Description: 2 classes a week, 90+minutes per class, general health education, excluding information on physical activity
Study: NCT01153243

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ergocalciferol
Description: Active Comparator: Ergocalciferol~The investigators will give intervention group 12 weeks of Vitamin D (ergocalciferol 50,000 units every week)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pill
Description: The investigators will give control group 12 weeks of 1 placebo pill every week.